We describe a series of Epstein Barr virus (EBV)positive circumscribed, ulcerative lesions associated with various types of immunosuppression (IS). The study group (26 patients) comprised 10 males and 16 females, median age 77 years (range 42 to 101). IS in 9 cases included azathioprine (AZA), methotrexate (MTX) or cyclosporin-A (CyA). Seventeen patients had age-related immunosenescence. Patients presented with isolated sharply circumscribed ulcers involving oropharyngeal mucosa (16), skin (6), and gastrointestinal tract (4). Lesions were histologically characterized by a polymorphous infiltrate and atypical large B-cell blasts often with Hodgkin/Reed-Sternberg (HRS) cell-like morphology. The B cells showed strong CD30 and EBER positivity, some with reduced CD20 expression, in a background of abundant T cells. CD15 was positive in 43% of cases (10/23). The pathologic features were identical regardless of the anatomic site or cause of IS. Polymerase chain reaction revealed 39% (7/18) clonal Ig gene rearrangements with 38% (6/16) and 31% (5/16) clonal and restricted T-cell patterns, respectively. Twenty-five percent of patients (5/20) received standard chemotherapy and/or radiotherapy. Forty-five percent (9/20) regressed spontaneously with no treatment and 15% (3/20) were characterized by a relapsing and remitting course. All of the iatrogenic lesions (6/6) with available follow-up responded to reduction of IS. All patients achieved complete remission with no disease-associated deaths over a median follow-up period of 22 months (range 3 to 72). We propose EBV-positive mucocutaneous ulcer as a newly recognized clinicopathologic entity with Hodgkin-like features and a self-limited, indolent course, generally responding well to conservative management. Association with various forms of IS implies a common pathogenetic mechanism. The localized nature of the disease may be owing to a minimal and localized lapse in immunosurveillance over EBV.
I n patients with various types of IS, the Epstein Barr virus (EBV) has long been associated with B-cell lymphoproliferative disorders. After primary infection at an early age EBV persistently infects B cells of most adults. The virus elicits B-cell transformation and proliferation through complex mechanisms. The products of viral genes upregulate a variety of cellular antigens and expression of genes in B cells. Key molecular pathways controlling the cell cycle, such as NF-kB, are activated and virus-induced cytokines exert paracrine proliferative effects. 28, 35, 38, 70 In physiologic circumstances the inherent propensity of EBV to induce B-cell proliferation is counterbalanced by complex immunologic interactions that maintain the overall number of EBV-infected B cells in the body at a very low level. 55 Immunosuppression affects various aspects of immune homeostasis and surveillance, thus permitting the emergence of EBV-induced B-cell lymphoproliferative disorders (EBV-LPDs). The spectrum of immunosuppressive etiologies resulting in EBV-LPDs has expanded to include primary immune deficiency, HIV infection, posttransplant setting, and other iatrogenic causes such as MTX and TNF-a antagonists. They affect reactivity of the immune system to EBV-infected cells in a variety of ways. 1, 7, 21, 32, 53, 62 Immunosenescence owing to ageing has recently been recognized as a cause of EBV-positive diffuse large B-cell lymphoma in elderly patients. 50, 51, 60, 61 In the elderly, the T-cell response seems most profoundly affected, with the accumulation of clonal CD8 positive T-cells with mature, memory cell phenotypes but diminished functionality, owing to a markedly restricted epitope specific repertoire. Thus, in advanced age there is a 100-fold decrease of T-cell specificities compared with a young immunocompetent individual. 16, 18, 30, 31, 42, 43, [46] [47] [48] [49] 52, 56, 67, 69 The pathologic features of EBV-LPDs arising in the setting of immune suppression (IS) are diverse and often shared among different types of immunosuppressive disorders. 1 However, the spectrum differs depending on the etiology of IS. Polymorphous lesions, best characterized in posttransplant EBV-LPD, occur with all types of IS. In patients receiving MTX therapy there is a higher incidence of classical Hodgkin's lymphoma (cHL) or Hodgkin-like lesions. A polymorphous form of diffuse large B-cell lymphoma (DLBCL) has been described in the elderly related to decreased immune surveillance and incorporated as a provisional subtype of DLBCL in the 2008 WHO classification. 1, 26, 27, 32, 45, 50, 51, 60, 61 However, overlap exists, and reactive lymphoid hyperplasia associated with EBV also has been described in the context of advanced age. [34] [35] [36] Despite better characterization and improved classification, diagnosis, and management of EBV-LPDs is still problematic. Pathologic assessment in many instances provides limited prognostic information and management often relies on clinical parameters and empirical decisions. Additional features to aid prognostication and indications for aggressive therapy are still being sought.
In our diagnostic practice, we have encountered lymphoproliferative lesions presenting as isolated cutaneous and mucosal ulcers during IS with MTX, AZA, CyA, or in elderly patients not receiving immunosuppressive agents. The pathologic features of these lesions have not been consistently described in the literature. We provide an analysis of 26 cases with a view to highlighting their distinctive pathologic appearances and characteristic clinical behavior and propose that these lesions constitute a new clinicopathologic category. We provide discussion on the possible common pathogenetic mechanisms of EBV-induced mucocutaneous ulcer in different IS settings including old age. Circumstances resulting in localized and self-limiting disease are analyzed together with the morphologic differential diagnosis, prognostic significance, and therapeutic implications.
MATERIALS AND METHODS

Case Selection
The cases were selected from the files of the Laboratory of Pathology of the National Cancer Institute (Bethesda MD) and All Wales Lymphoma Panel (AWLP) (Cardiff, UK). The source included primary diagnostic material and second opinion referrals from pathology departments across the United States and 17 departments of pathology in Wales over a total period of 15 years. The initial selection included all cases of EBV-LPD with significant expression of EBER on in situ hybridization exceeding that seen in normal lymphoid tissue. 22 These were excluded: patients with a previous history of lymphoma; lymphoma entities in which the presence of EBER in the neoplastic cells or background infiltrate represents a diagnostic requirement, for example, lymphomatoid granulomatosis (LyG), DLBCL associated with chronic inflammation, primary effusion lymphoma, plasmablastic lymphoma. Well-circumscribed, isolated ulcerating lesions presenting in the skin or on mucosal surfaces were selected from this wider group. For the lesions matching the selection criteria we designated the term ''EBV Associated Mucocutaneous Ulcer'' (EBVMCU).
Adequately fixed and processed tissue material was available together with detailed clinical history.
Histologic Assessment
The biopsy material was fixed in 10% formalin and embedded in paraffin after routine histologic tissue processing. Three to 4-mm histologic sections were stained with H&E for microscopic examination.
Immunohistochemistry
Immunostaining on paraffin sections was done for CD3, CD4, CD8, CD20, CD30, and CD15. For additional characterization of the lesional cells a proportion of cases were immunostained for CD45, CD79a, MUM1, PAX5, Oct-2, Bob.1, CD138, LMP1, CD10, and BCL-6. Staining was done with an automated immunostaining system, either DAKO Autostainer+(AWLP cases) ( Table 1) or Ventana Medical Systems (Tucson, AZ) (NCI cases), with antigen retrieval and antibody dilutions per manufacturer's recommendation and as previously published. 71 
In Situ Hybridization
In situ hybridization for EBV-encoded RNA (EBER) was conducted on formalin-fixed paraffin sections using a FITC labeled oligonucleotide probe supplied by Ventana on an automated stainer (Ventana-Benchmark). Visualization was achieved using the ISH iView system with Alk-Phosphatase and NT/BCIP substrate, with Fast red as contrast.
Polymerase Chain Reaction (PCR) for Immunoglobulin (IG) and T-cell Receptor (TCR) Gene Rearrangements
For NIH cases PCR analysis was done using a routine diagnostic protocol with inhouse custom made primers. DNA was extracted from formalin-fixed paraffinembedded tissue blocks using a standard protocol. For IgH rearrangements DNA amplification by PCR was conducted using Framework Region III primers. 57, 58 Additional seminested PCR amplifications were carried out using primers to Framework Region II of the immunoglobulin heavy chain gene according to the method of Ramasamy et al. 54 Cases negative for IgH rearrangement were further studied for rearrangements of the IGk locus using the Biomed II primer set described by van Dongen et al 65 and supplied by InVivoScribe Technologies (IGK Gene Clonality Assay-ABI Fluorescence Detection). These reactions interrogate rearrangements involving the Vk loci and Jk (Tube A), the Vk locus and the kDE locus (Tube B), and the k intron RSS locus and the kDE locus (Tube B). The products were analyzed by capillary electrophoresis on an ABI 3130 Genetic Analyzer, and electropherograms were analyzed using GeneMapper software version 3.7 (ABI). For TCR gene rearrangements amplification was done using primers to the TCR g chain gene. 40 Two separate reactions were carried out for each extract, 1 with primers V-g-101, J-g-11 and J-g-12 (set 1), and a second with primers V-g-101, V-g-11, and Jp12 (set 2).
All the amplification reactions were carried out in duplicate. The products were analyzed by acrylamide gel or capillary electrophoresis. The results were interpreted in conjunction with a blank (water), polyclonal and monoclonal control.
PCR analysis on the cases from the AWLP files was conducted using the Biomed 2 primers interrogating specific gene segments of the IgH, IGK, k deleting element, TCR-b and TCR-g gene rearrangements. DNA extraction and amplification from formalin-fixed paraffinembedded tissue was conducted using a standardized protocol. 14, 65 The tests were conducted in duplicate and the results were visualized by acrylamide gel electrophoresis and by GeneScan. The results were interpreted in conjunction with a blank, polyclonal, and monoclonal control.
RESULTS
Patient Characteristics
The demographic and clinical information is summarized in Table 2 . Twenty-six cases of EBVMCU were identified from 200 EBV positive B-cell LPDs. The study group comprised 10 male and 16 female patients with a median age of 77 (range 42 to 101). Nine patients were receiving therapeutic IS for an autoimmune condition [rheumatoid arthritis (5) , ulcerative colitis (1), sarcoidosis with myasthenia gravis (1) and systemic lupus erythematosus (1)] or allogeneic stem cell bone marrow transplantation (1). The median age of these patients was 69 (42 to 80). The IS regimens included standard therapeutic doses of MTX, AZA and CyA. For the remaining 17 patients there was no apparent source of IS. These patients were designated as age-related EBV-LPD. The median age was 80 years (range 64 to 101). The clinical presentation was characterized by slowly developing indurated ulcers, which in 16 cases involved oropharyngeal mucosa [buccal mucosa (2) , tongue (8) , tonsils (5), palate (1)]. Four patients each had oesophageal, large bowel (2) and rectal ulcers, respectively and 6 had lesions on the skin of the lips, arms and chest. Two patients had concomitant isolated unilateral neck lymphadenopathy (cases 9 and 13) but none had evidence of systemic lymphadenopathy, hepatosplenomegaly, or bone marrow involvement. In all patients with oropharyngeal or cutaneous lesions the clinical suspicion leading to biopsy was of a nonhematologic malignancy, usually thought to be squamous cell carcinoma. The esophageal, colonic and rectal lesions were on clinical grounds initially also considered to represent nonlymphoid tumors or inflammatory bowel disease. Upon request for pathology review, the submitted histologic diagnoses in 10 cases included classical Hodgkin lymphoma (5), diffuse large B-cell lymphoma (3) CD30 positive cutaneous T-cell lymphoproliferation (1) and EBV positive lymphoproliferative process (1) .
There was significant statistical difference between the age means of the age related and iatrogenic IS groups (t test, P exact = 0.021).
Clinical Course
Follow-up information was available for 20 of the 26 patients (Table 2) . Of the 17 patients with age-related EBVMCU, 3 had multiple episodes of oral mucosal ulceration with spontaneous resolution. Nine patients in this group did not receive any therapy. Of those with available follow-up, 1 patient (case 8) was deemed too frail for any treatment. He had stable persistent disease for 5 months and died of unrelated causes. After biopsy, there was spontaneous regression of 5 lesions in the agerelated group with no further evidence of disease after a median follow-up of 18 (3 to 36) months. Five patients with age-related EBVMCU were actively treated. One received chemotherapy, 2 had combined radiotherapy and chemotherapy whereas 3 had radiotherapy only. All treated patients remained in complete remission after a median follow-up of 15 months (range 3 to 60). All 6 patients with iatrogenic IS and available follow-up (cases 21 to 26) stayed in complete remission upon reduction of IS after a median follow-up of 23 months (range 6 to 60) (Figs. 1A-D). In all 26 cases there were no disease-related deaths after an overall follow-up of 22 months (3 to 72). Six patients died of unrelated causes. (AWLP cases 15, 21, to 26).
Histology
The morphologic features are summarized in Table 3 . All the lesions showed similar histologic features regardless of the nature of IS. These were shallow, sharply circumscribed mucosal or cutaneous ulcers ( Fig. 2A ). The underlying infiltrate seemed polymorphous with a mixture of lymphocytes and immunoblasts. Although scattered plasma cells, histiocytes, and eosinophils were generally present in all cases, in some they were deemed to be particularly prominent ( Table 3 , Figs. 2B, D). Scattered large pleomorphic blasts reminiscent of Hodgkin and Reed-Sternberg (HRS) cells were present in variable numbers in all cases (Fig. 2C ). The lymphocytes in the background were abundant, many with angulated and medium size nuclei. A constant finding was dispersed ''plasmacytoid'' apoptotic cells ( Fig. 2E ). These were variably sized cells with abundant basophilic cytoplasm and apoptotic nuclei frequently showing coarse radial distribution of clumped nuclear chromatin reminiscent of the ''cart-wheel'' nuclear appearance of plasma cells. In 6 cases the large lesional cells were seen infiltrating medium-size arteries with associated thrombosis (Fig. 2F ).
This was usually accompanied by surrounding necrosis in addition to surface ulceration, which in 1 case seemed very marked. The base of the lesions was sharply delineated by a rim of small lymphocytes (Fig. 2G ). The adjacent squamous epithelium showed reactive nuclear atypia, often with pseudoepitheliomatous hyperplasia. In the colon and rectum the infiltrate permeated between the intestinal crypts that were otherwise unremarkable (Fig. 2H ).
Immunohistochemistry
The immunophenotype of the B-cell blasts and cells with the HRS features is summarized in Table 4 . The pleomorphic HRS cells were of B-cell phenotype (Fig. 3A) . The lesional blasts were unequivocally positive for CD45 in 56% of cases (5/9) and showed no expression of this marker in 11% (1/9). Owing to positivity in the background cells expression of CD45 could not be assessed with confidence in 33% of cases (3/9). There was reduced or absent expression of CD20 in 31% of cases (8/26) ( Fig. 3B ) and in a small proportion of tested cases the pleomorphic lesional blasts seemed positive for PAX5 and Oct-2 with variable expression of Bob.1 ( Table 4 ; Figs. 3C-E). These cells were strongly positive for CD30 and in 43% of cases (10/23) coexpressed CD15 (Figs. 3G, H) . The cells positive for CD20, CD30, Oct-2 and PAX5 varied in size, ranging from small lymphocytes to larger immunoblasts to pleomorphic HRS-like cells. In all tested cases these cells were positive for MUM1 (8/8) ( Fig. 3F ) with no expression of CD10 and absent or focal positivity for BCL6. In all but 1 case tested (8/9) the lesional blasts were positive for LMP1 ( Fig. 4B ) 
In Situ Hybridization
In situ hybridization for EBER in all cases showed abundant staining highlighting a range of nuclear sizes, from small lymphocytes to immunoblasts and large pleomorphic cells with HRS cell morphology (Fig. 4C) . Positivity for EBER co-localized with the expression of LMP1, CD20, and PAX5. In cases with identifiable angioinvasion, EBER positive blasts were seen scattered within vessel walls. EBER also highlighted the circumscribed nature of the lesions, displaying a band-like positivity underlying the ulcerated surface (Fig. 4A) . No staining could be seen within the epithelium.
PCR for IG and TCR Gene Rearrangements
A PCR result could be obtained in 18 cases (Table 5 ). Eighteen and 16 cases were successfully tested for IG and TCR gene rearrangements respectively. In 3 cases no DNA amplification could be achieved and 5 cases could not be tested. Monoclonal IG rearrangement was found in 7 cases (38.9%). There was monoclonal TCR gene rearrangement in 6 cases (37.6%). A pattern characterized by multiple prominent irregular bands or peaks, on gels or genescan plots respectively, was considered to represent evidence of ''restricted'' T-cell response (Figs. 4D, E) . Such a pattern was detected in 5 cases (31.2%). The cases with clonal or restricted T-cell patterns were not confined to any particular IS type and there was no significant difference in the proportions of clonal/restricted TRG between the 2 groups (Fisher test, 2-sided P exact = 1.00). A monoclonal or restricted T-cell response was seen in 60% (6/10) of age-related cases and in 83.3% (5/6) of those associated with iatrogenic IS. A monoclonal IG rearrangement was accompanied by a restricted T-cell response in 3 cases.
DISCUSSION
We describe a series of localized mucosal and cutaneous ulcerative EBV positive LPDs with polymorphous and Hodgkin-like morphology and immunophenotype. This proliferation was associated with advanced age and varied forms of medication-induced IS for autoimmune disorders and bone marrow stem cell transplantation. Despite the presence of highly atypical cells, the clinical course was indolent, without progression to disseminated disease in any patient, and spontaneous remissions were seen in several cases. Thus, the distinctive clinical and pathologic features of these lesions warrant special recognition, and separation from other EBV-LPDs. As the nature of the IS in our cases was variable, this implies the possibility of a common pathogenetic mechanism across different types of IS including the post transplant setting, although interestingly, no HIV infectionassociated cases were observed.
Lesions resembling EBVMCU have been reported previously, most often in association with MTX. 3, 25 Most regressed upon withdrawal of the drug and were regarded a consequence of a toxic/metabolic effect rather than EBV related. Microscopically, they were reported to show nonspecific ulceration but the majority of reported cases were not histologically assessed. 12, 13, 29 Similar lesions have also been seen with CyA in the post transplant setting, 6 most often affecting the oropharyngeal mucosa. 45 Age-related EBV-LPDs have a high incidence of extranodal presentation involving skin and tonsils in 13% and 8% of cases, respectively. However, in the literature published on this topic so far, it is difficult to identify with certainty cases similar to ours. 50, 51 Our study identifies EBVMCU as a distinctive lesion that can occur in a variety of clinical settings associated with defective immune surveillance for EBV, including advanced age in a high proportion of cases. In our series all cases harbored large atypical blasts, often with HRS cell morphology, in a polymorphous background as may be seen in cHL. The large blasts showed reduced level of expression of CD20 with retained positivity of PAX5 and Oct-2 but with variable expression of Bob.1. Although CD30 was uniformly positive, expression of CD15 varied, being coexpressed in 43.5% of cases. The lesional blasts showed a postgerminal centre phenotype, generally lacking expression of CD10 and BCL6, with strong positivity for MUM1, as often seen in cHL. However, in most of the tested cases (8/9) the HRSlike cells were CD45 positive.
A combination of clinical, morphologic, and immunophenotypic parameters is useful in reaching the correct diagnosis. EBV-LPDs frequently harbor prominent immunoblasts, and HRS-like cells have been described in many settings, including acute infectious mononucleosis. However, the phenotype varies, and in *Significance of differences in proportions of clonal IGH and clonal/restricted TCR cases across the two groups (Age-related and iatrogenic IS) were examined by Fisher exact test using SAS 9.2 (SAS institute, Cary, NC). There was no significant differences in the proportions of clonal IGH or clonal/restricted TCR cases between both group (2-sided pexact = 1.00 for both analyses).
wClonality per institution: AWLP cases: IG-PC (n = 3); C (n = 4). TCR-PC (n = 1); C (n = 2); R (n = 4). NIH cases: IG-PC (n = 8); C (n = 3); TCR-PC (n = 4); C (n = 4); R (n = 1). C indicates clonal; IG, immunoglobulin; TCR, T-cell receptor; PC, polyclonal; R, restricted. infectious mononucleosis and PTLD, the HRS-like cells are CD30 positive but CD15 has been reported negative. 8, 10 In EBV-LPDs associated with MTX therapy, the lack of expression of CD15 in CD30 positive HRS-like cells also has been considered a feature against the diagnosis of cHL. 27 Asano et al 2 also have investigated Hodgkin-like features in age-related DLBCL. Indications for a diagnosis of DLBCL rather than cHL in their study included involvement of extranodal sites, prominent necrosis, abundance of cytotoxic T-cells, higher positivity for CD20 and EBNA2, and lack of expression of CD15. In fact, the absence of CD15 was used as a major discriminatory factor, in that no case of age-related DLBCL was CD15-positive. 50, 51 Our study indicates that CD15 expression clearly can occur in EBV-positive lesions outside of the diagnosis of cHL, and that one must be cautious in considering the presence or absence of CD15 as an independent determining factor, particularly in lesions involving extranodal sites. cHL seldom involves extranodal sites; in particular, primary mucosal or cutaneous involvement is considered exceptionally rare, if it occurs at all. 2, 8 An additional useful parameter not typical for cHL was the wide range in cell size of the EBV-positive cells as highlighted by CD20, CD30 and EBER. Typically, these included some small lymphocytes, immunoblasts, and large HRS-like cells which, unlike in cHL, were CD45 positive.
EBVMCU has distinctive pathologic features that may be regarded as hallmarks of the condition. Notable features are the well circumscribed and superficial nature of the lesions with a characteristic architecture in the form of a prominent rim of small T-lymphocytes at the base. The infiltrates contain abundant CD8 positive T-cells and large numbers of EBV-positive plasmacytoid apoptotic cells, both not common features of cHL. Considering apoptosis, it has been proposed that EBV may be able to rescue germinal centre cells from undergoing apoptosis. It can provide the CD40-mediated survival stimulus resulting in the perpetual activation of the NFkB pathway, stimulating proliferation, and abrogating apoptosis. Abundant apoptosis is not a prominent feature of EBV-associated cHL and thus, the presence of prominent apoptotic cells in EBVMCU may be a hallmark of retained normal control mechanisms and lack of a transformed phenotype, as seen in EBV-positive lymphomas such as cHL. 64 The HRS-cells of cHL typically lack the transcription factors Oct-2, Bob.1 and PU1, retaining weak expression of PAX5. 15, 41, 64 Although the number of cases analyzed was small, partial loss of expression of Bob.1 seen in our series further resembles the immunophenotype of cHL, and should not by itself prompt a diagnosis of cHL.
Finally, the presence of vasculitic changes in some cases might suggest a differential diagnosis with LyG. The underlying pathogenetic mechanism of vascular change might be similar to LyG. LMP1 seems to stimulate secretion of interferon-g-inducible-protein-10 and a monokine induced by INF-g facilitating vascular damage and necrosis. 11, 63 Cutaneous or mucosal involvement in the absence of pulmonary presentation would argue against the diagnosis of LyG. 4, 24, 59 In LyG the background infiltrate is composed almost exclusively of T-cells with relatively few EBV positive B-cell blasts whereas in EBVMCU there was a more polymorphous infiltrate containing lymphocytes, plasma cells, histiocytes, and eosinophils. 17 Results of clonality studies of EBVMCU may provide some insight into underlying pathogenesis. The focus of clonality assessment in IS EBV-LPDs has always been on the lesional B-cell population. However, recent studies have shown that defective control of EBV may be related to a diminished T-cell repertoire and an inability to recognize the full range of EBV-epitopes. 5 In addition, it has been shown that clonally restricted T-cell populations may be detected in the response to EBV, 6 and in association with some EBV-driven LPD's secondary to iatrogenic immunosuppression. 3 Clonal T-cell expansion is a feature of incomplete control of EBV, and is more often found in patients with symptomatic disease. 11 The nature of the T-cell response to EBV has not been extensively studied in age-related EBV LPDs. Seventeen patients from our study group had no evidence of IS other than advanced age beyond 60. With ageing the complex spectrum of regressive changes affecting the immune system are collectively termed immunosenescence. 13, 23, 61, 66 T-cell responses seem most profoundly affected, with the accumulation of clonal CD8 positive T-cells with mature, memory cell phenotypes but diminished functionality. This seems to be a result of a decline in the capacity to generate a pool of new, naive T-cells, which is compensated for by proliferation within the mature senescent memory cell pool. The result is prevalence of oligoclonal T-cell populations in elderly subjects (''restricted'' T-cell response) that are markedly restricted and deficient in their epitope specific repertoire, rendering the host at increased risk of infection. The underlying mechanisms are complex including exhaustion of the T-cell response and diminished capacity to renew the pool of virgin T-cells. 16, 18, 42, 43, 52 In our series monoclonal TCR gene rearrangement was seen in 38% of cases. Evidence of ''restricted'' T-cell response was noted in another 31% of cases and a monoclonal IG rearrangement was accompanied by a restricted T-cell response in 3 cases. This finding is compatible with a limited T-cell repertoire to EBV in patients with EBVMCU, reflecting deficiency in T-cell control, rather than being a secondary event.
Evidence of clonality as demonstrated by clonal IG gene rearrangement is variably present in EBV-LPDs, and correlates to some extent with the clinical findings. Most cases of PTLD, both polymorphic and monomorphic, are clonal, at least in individual lesions. 33 Most cases of age-related DLBCL in the Japanese cohort also showed evidence of B-cell clonality. 50, 51, 61 In EBVMCU, we found PCR evidence of B-cell clonality in 39% (7/18) of cases, with a similar rate of rearrangements in the age related and iatrogenic groups. The lack of demonstrated monoclonality may suggest that these lesions are not true B-cell neoplasms.
A number of untreated cases from our series exhibited either spontaneous regression, or had persistent but limited disease confined to the skin or mucosa. Such clinical behavior suggests a possibility of partial and minimal reduction in immunosurveillance over EBV. The question arises as to why does such a lapse in immunity presents itself in mucosal sites and skin. No specific pathologic clues could be identified to explain this phenomenon. One possible explanation may be that in normal circumstances, concentration of EBV-infected B cells seems the highest in the Waldeyer's ring. 39 The majority of our cases involved oropharyngeal sites; however, such data for other mucosal sites and skin are not available. An additional speculative explanation might be related to minor localized mucosal irritation (eg, from dentures) or mucocutaneous injury, creating a point of lowered resistance for localized proliferation of EBV-infected cells, which is then ''walled off'' by a brisk T-cell reaction. All the lesions seem very well demarcated from the surrounding structures and encircled by a dense rim of lymphocytes. Chronic inflammation has been implicated as a cause of other EBV-related B-cell proliferations, most often involving chronic pyothorax. 9, 23, 44 Interestingly, EBVMCU was associated with a variety of forms of IS. Immunosuppressive agents in our series included MTX, AZA and CyA. These are used for treatment of a range of idiopathic inflammatory and autoimmune conditions. AZA and CyA are also used in solid organ transplant recipients although in this patient population the extent of immunosuppression may be more profound than in patients with autoimmune disease. Association of these agents with LPDs has been studied previously. 1, 7, 21, 32, 53, 62, 66, 68 Interestingly, a prior report of EBV-associated cHL (or Hodgkin-like lesions) in patients with inflammatory bowel disease identified features very similar to our cases of EBVMCU. Two of the 4 patients had received AZA. 37 Age may be a confounding feature in the patients in whom EBVMCU was linked to iatrogenic immunodeficiency. Notably, even in this group the median age was 69, in comparison to the ''age-related'' group in which the median age was 80. We found evidence for clonal and restricted T-cell responses in both these groups, but there was no significant difference in proportions of clonal/ restricted TRG across both groups (Fisher test, 2-sided P exact = 1.00).
It is possible that in a minority of people T-cell incompetence related to the ageing process alone reaches a critical level such that in sites in which EBV-infected cells are more abundant, the localized EBV driven B-cell LP is established. Effective immunosurveillance may be ''on the cusp'' and potentially reversible. Thus, in 3 of our patients there was clinical evidence of waxing and waning lesions. However, in a proportion of patients, the additional administration of an immunosuppressive agent might tip the balance towards loss of local immunosurveillance over EBV-infected B cells. MTX directly induces EBV replication by activating viral early promoters. 17 There is also evidence of CyA induced, oxidative stress mediated, direct EBV activation of B-cells. 3, 68 These effects could be responsible for localized increase in the content of EBV-infected cells in the anatomical sites in which the virus seems most prevalent. Such a scenario might potentially explain why administration of various immunosuppressive medications, with different mechanisms of action, result in the same type of lesion. Significant statistical difference in the mean ages of patients with and without iatrogenic IS respectively confirms the assumption that age alone plays an important etiologic role.
The therapeutic approach in EBV-LPDs depends on a variety of factors. In the post transplant setting prospects for graft survival needs to be considered as well. When possible, reduction of IS is the first management step, but of course is not possible in patients in whom immune senescence is the underlying cause. In the age-related cases 21% had a relapsing and remitting character, with spontaneous complete remission in 57% of cases (in 6/14 the outcome is unknown). However, 36% of the age-related EBVMCU received aggressive therapy, which might further compromise the host immune system. The overall outcomes of EBVMCU highlight an indolent and self-limited condition, arguing for a conservative therapeutic approach, possibly including rituximab therapy or agents capable of enhancing immunologic control over EBV. 11, 19, 20 The incidence of EBVMCU is difficult to establish with certainty. As diagnosis of all lymphomas in Wales is made centrally and most atypical LPDs are referred for central review, some estimation can be drawn. With the exception of 1 case which was an external referral, 6 cases originated from the Welsh population of 3 million over a period of 5 years (2004 to 2009) at a rate of approximately 1 case per year. However, the spontaneously remitting nature of the EBVMCU is likely to result in empirical conservative management without biopsy in many cases, thus resulting in an underestimated incidence. Literature reports of MTX associated mucosal and skin ulcers that were not accompanied by pathologic assessment make this assumption likely. 12, 25, 29 In the most recent WHO classification update EBV-LPD's are grouped under separate headings depending on underlying etiology and clinical setting. EBV-positive DLBCL of the elderly is included as a provisional subtype of DLBCL, but is described as a clinically aggressive form of lymphoma with poor outcome in most patients. Therefore, it is important to draw attention to EBVMCU as a more indolent form of EBV-LPD occurring in the same age group, but requiring a different management approach.
In summary, EBV-associated mucocutaneous ulcer is a new rare pathologic entity associated with IS from a variety of origins, suggesting a common pathogenetic mechanism. Typified by an isolated and circumscribed cutaneous and mucosal presentation, it has an indolent behavior and a self-limited clinical course. It may result from a minimal and localized lapse in immunosurveillance over EBV. The high regression rate upon withdrawal of IS and a waxing and waning course in age-related cases point to a condition for which conservative management is advised. The morphologic and immunophenotypic features to a certain extent resemble cHL, in particular with a high percentage of CD15 positivity. However, correct diagnosis is facilitated by consideration of the clinical history and the observed spectrum in the EBV-positive cells.
